A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

Trial Profile

A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs BGB 3111 (Primary)
  • Indications B cell lymphoma
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 10 May 2017 According to a BeiGene media release, the follow-up of enrolled patients is ongoing.
    • 22 Mar 2017 According to a BeiGene media release, updated data will be presented in 2017.
    • 18 Mar 2017 Results presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top